Last week, A2 opened a new production facility in Sydney to cope with growing Australian demand as it prepares to launch New Zealand-produced infant formula into China and expand into Britain through a joint venture with Robert Wiseman Dairies.
The British "trading environment is challenging, but we have a unique offering", Babidge said.
A2 expects its first production of infant formula, supplied by Synlait Milk, in December, and Babidge said talks with a partner in the Chinese market were well advanced.
"It's a very big market, particularly for New Zealand-sourced infant formula."
Babidge said the strategic review of the business would be considering A2's domicile after shareholders last year agreed to a new constitution that allows for the NZAX-listed stock to be transferred to the New Zealand stock exchange's main board or to the ASX.
The shares rose 2.2 per cent to 47c and have surged 100 per cent this year.
The review is still underway, and Babidge said A2 would update the market when it was completed.
The board did not declare a dividend.